Poster 102: Short and Long Term Efficacy of Ultrasound Guided Sacroiliac Joint Injections When Combined with Physical Examination and Point of Maximal Tenderness

PM&R ◽  
2017 ◽  
Vol 9 ◽  
pp. S168-S168
Author(s):  
Douglas E. Hemler ◽  
Patrick J. Wallace ◽  
Laurie M. Bezjian ◽  
Kyle C. Morgan
Keyword(s):  
Physical Examination ◽  
Sacroiliac Joint ◽  
Ultrasound Guided ◽  
Term Efficacy ◽  
Short And Long Term ◽  
Joint Injections

Long-term efficacy of ultrasound-guided laser ablation for solid thyroid nodules. A three-year multicenter prospective randomized trial

2014 ◽  
Author(s):  
Enrico Papini ◽  
Teresa Rago ◽  
Giovanni Gambelunghe ◽  
Roberto Valcavi ◽  
Giancarlo Bizzarri ◽  
...  
Keyword(s):  
Laser Ablation ◽  
Randomized Trial ◽  
Thyroid Nodules ◽  
Prospective Randomized Trial ◽  
Ultrasound Guided ◽  
Term Efficacy

scholarly journals AB0642 SACROILIAC JOINT INJECTIONS PERFORMED WITH ULTRASOUND GUIDANCE IN PATIENTS WITH SACROILIITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1615.2-1616
Author(s):  
A. R. Cunha ◽  
C. Mazeda ◽  
R. Aguiar ◽  
A. Barcelos
Keyword(s):  
Sacroiliac Joint ◽  
Ultrasound Guidance ◽  
Disease Duration ◽  
Corticosteroid Injection ◽  
Controlled Study ◽  
Ultrasound Guided ◽  
Sonographic Guidance ◽  
Number Of Patients ◽  
Joint Injections

Background:Sacroiliitis is the hallmark of axial Spondyloarthritis (axSpA). ASAS-EULAR management recommendations for axSpA, consider glucocorticoid injections directed to the local site of musculoskeletal inflammation as a treatment option for pain relief, besides treatment with oral non-steroidal anti-inflammatory (NSAIDs) before starter biotechnological treatment. However, there are few studies to evaluate efficacy of this technique with a small number of patients and a short follow-up. Ultrasonography has been used as a valuable option to guide this technique.Objectives:To evaluate the efficacy and safety of ultrasound-guided injections of sacroiliac joints (SIJs) in patients with sacroiliitis using clinical and laboratory outcomes at baseline and at 4-6thweeks.Methods:This study involved patients with axSpA with acute sacroiliitis, ≥18 and ≤ 65 years old, with body mass index (BMI) < 30kg/m2attending the Rheumatology Outpatient Clinic, which had been poorly controlled (ASDAS>2.1) by conventional therapy (physiotherapy, NSAIDs at maximum tolerated dosing during ≥ 4 weeks). Sociodemographic, clinical (disease duration, BMI, BASDAI, BASFI, ASDAS) and laboratory (CRP) data was collected from the medical records at baseline and at 4-6thweeks.Statistical analyses were conducted using SPSS version 25. Continuous variables were described with mean/median ± standard deviation (SD).SIJs injection was performed, under ultrasound guidance, using standard procedures with 2mL of lidocaine 1% and 40mg of methylprednisolone, with a 22-gauge needle. The procedure was performed by the same operator. Written informed consents were obtained from all patients.Results:We performed eleven sacroiliac injection in eleven consecutive patients (one procedure per patient). Nine patients (81.8%) were female, mean age (±SD) of 40.6(±9.4) years, median disease duration(±SD) of 0.9(±6.2) years and median BMI(±SD) of 24.2(±3.3). Eight patients (72.7%) had Nr-axSpA. All patients were non-responders to NSAIDs.At 4-6thweeks there was a decreased in median (±SD) BASDAI (5.4±1.9 vs 4.1±1.9), BASFI (4.2±1.4 vs 3.5±2.3) and ASDAS (3.2±0.8 vs 2.2±0.6) indexes.Conclusion:As previous studies demonstrated, this technique seems to be safe and quite effective.Our goal is to increase the number of patients undergoing this technique and have a longer follow up to evaluate its efficacy. The study has several limitations: the mid- and long-term effects should be evaluated in the future based on the results of the short-term effects and the study was not conducted as a double-blinded, controlled study.References:[1]van der Heijde D, Burgos-Vargas R, Ramiro S.,et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2017; 76:978–991[2]Maugars Y, Mathis C, Vilon P, Prost A. Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. Arthritis Rheum 1992; 35:564–8.[3]Pekkafahli MZ, Kiralp MZ, Basekim CC et al. Sacroiliac joint injections performed with sonographic guidance. J Ultrasound Med 2003;22:553–9[4]Klauser A, De Zordo T, Feuchtner G et al. Feasibility of ultrasound-guided sacroiliac joint injection considering sonoanatomic landmarks at two different levels in cadavers and patients. Arthritis Rheum 2008; 59:1618–1624.Disclosure of Interests:Ana Rita Cunha: None declared, Carolina Mazeda: None declared, Renata Aguiar: None declared, Anabela Barcelos Speakers bureau: Bene, Eli-Lilly, Pfizer, MSD, Novartis

Rituximab in Previously Treated Primary Immune Thrombocytopenia Patients: Evaluation of Short- and Long-Term Efficacy and Safety

2013 ◽  
Vol 132 (1) ◽  
pp. 24-29 ◽  
Author(s):  
Cristina Santoro ◽  
Francesca Biondo ◽  
Erminia Baldacci ◽  
Maria Stefania De Propris ◽  
Anna Guarini ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Efficacy And Safety ◽  
Term Efficacy ◽  
Primary Immune Thrombocytopenia ◽  
Previously Treated ◽  
Short And Long Term

Long-term efficacy evaluation of a protocol for the management of symptomatic thyroid cysts with ultrasound-guided percutaneous ethanol injection

2021 ◽  
Vol 68 (4) ◽  
pp. 236-242
Author(s):  
Jordi L. Reverter ◽  
Federico Vázquez ◽  
Carlos Puig-Jové ◽  
Alejandra Pérez-Montes de Oca ◽  
Manuel Puig-Domingo
Keyword(s):  
Percutaneous Ethanol Injection ◽  
Ultrasound Guided ◽  
Efficacy Evaluation ◽  
Ethanol Injection ◽  
Term Efficacy

18 Short- and long-term efficacy of intensive rehabilitation treatment on balance and gait in Parkinsonian patients: A pilot study with a 1-year follow-up

Basal Ganglia ◽  
2012 ◽  
Vol 2 (4) ◽  
pp. 262
Author(s):  
G. Frazzitta ◽  
G. Bertotti ◽  
P. Balbi ◽  
D. Uccellini ◽  
N. Boveri ◽  
...  
Keyword(s):  
Pilot Study ◽  
Rehabilitation Treatment ◽  
Term Efficacy ◽  
Short And Long Term ◽  
Intensive Rehabilitation

scholarly journals Corticosteroid injection for coccydynia

2020 ◽  
Vol 1 (11) ◽  
pp. 709-714
Author(s):  
Vilhjalmur Finsen ◽  
Ante M. Kalstad ◽  
Rainer G. Knobloch
Keyword(s):  
Logistic Regression ◽  
Confidence Interval ◽  
Odds Ratio ◽  
Corticosteroid Injection ◽  
Term Efficacy ◽  
Early Success ◽  
Cortisone Injection ◽  
Short And Long Term ◽  
Regression Tests

Aims We aimed to establish the short- and long-term efficacy of corticosteroid injection for coccydynia, and to determine if betamethasone or triamcinolone has the best effect. Methods During 2009 to 2016, we treated 277 patients with chronic coccydynia with either one 6 mg betamethasone or one 20 mg triamcinolone cortisone injection. A susequent injection was given to 62 (26%) of the patients. All were reviewed three to four months after injection, and 241 replied to a questionnaire a mean of 36 months (12 to 88) after the last injection. No pain at the early review was considered early success. When the patient had not been subsequently operated on, and indicated on the questionnaire that they were either well or much better, it was considered a long-term success. Results At the three- to four-month review, 22 (9%) reported that they had no pain. The long-term success of one injection was 15% and rose to 29% after a second injection. Logistic regression tests showed that both early success (odds ratio (OR) 5.5, 95% confidence interval (CI) 2.1 to 14.4; p = 0.001) and late success (OR 3.7, 95% CI 1.7 to 8.3; p = 0.001) was greater with triamcinolone than with betamethasone. Late success was greater for patients with symptoms for less than 12 months (OR 3.0, 95% CI 1.4 to 6.7; p = 0.006). We saw no complications of the injections. Conclusion We conclude that the effect of corticosteroid injection for coccygodynia is moderate, possibly because we used modest doses of the drugs. Even so, they seem worthwhile as they are easily and quickly performed, and complications are rare. If the choice is between injections of betamethasone or triamcinolone, the latter should be selected. Cite this article: Bone Joint Open 2020;1-11:709–714.

scholarly journals Fissurectomy combined with botulinum toxin A: a review of short- and long-term efficacy of this treatment strategy for chronic anal fissure; a consecutive proposal of a treatment algorithm for chronic anal fissure

2020 ◽  
Vol 42 (5) ◽  
pp. 400-408
Author(s):  
M. Trzpis ◽  
J. M. Klaase ◽  
R. H. Koop ◽  
P. M. A. Broens
Keyword(s):  
Botulinum Toxin ◽  
Anal Fissure ◽  
Recurrence Rate ◽  
Treatment Strategy ◽  
Chronic Anal Fissure ◽  
Botulinum Toxin A ◽  
Toxin A ◽  
Term Efficacy ◽  
Short And Long Term

Abstract Background Several studies have investigated the short- and long-term efficacy of fissurectomy combined with botulinum toxin A injection for patients with chronic anal fissure. Objective To evaluate the short- and long-term efficacy of the combined treatment strategy of fissurectomy with botulinum toxin A for chronic anal fissure and to discuss recurrence rates in the light of current theory on the aetiology of anal fissure. Materials and methods This is a narrative review. We conducted an article search using PubMed and calculated the means of the reported efficacy ranges. Results Fissurectomy combined with botulinum toxin A injections freed at least 78% of the patients from symptoms and yielded a fissure healing rate of up to 86%. Within 12 months after treatment a 3% recurrence rate was reported. On average, the long-term recurrence rate was 22%. One study reported a 50% recurrence rate 22 months after treatment. Conclusion The efficacy of fissurectomy combined with botulinum toxin A injection for chronic anal fissure is high. The short-term recurrence rate is low, while long-term recurrence is relatively high. Extended follow-up indicates that recurrence of chronic anal fissure is possibly caused by anal basal pressure building up steadily once again. If so, the cause of renewed increase of pressure should be addressed. Based on the literature and on our clinical experience, we assume that the underlying cause of increasing anal basal pressure is that patients use their pelvic floor muscles inadequately and this in turn leads to chronic anal fissure.

Sign in / Sign up

Export Citation Format

Share Document